Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

Abstract Background The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initial estimate of the dose-toxicity relationship (prior skeleton) is requir...

Full description

Bibliographic Details
Main Authors: G. D. James, S. Symeonides, J. Marshall, J. Young, G. Clack
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Clinical trial
Phase 1
Continual reassessment method
Skeleton
Bayesian
Oncology
Online Access:https://doi.org/10.1186/s12885-020-07703-6

Internet

https://doi.org/10.1186/s12885-020-07703-6

Similar Items